New Risk • May 06
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$37m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$37m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (33% increase in shares outstanding). Revenue is less than US$1m (NT$27m revenue, or US$852k). Market cap is less than US$10m (NT$276.2m market cap, or US$8.76m). Reported Earnings • Apr 22
Full year 2025 earnings released: NT$1.37 loss per share (vs NT$2.05 loss in FY 2024) Full year 2025 results: NT$1.37 loss per share. Revenue: NT$26.9m (up 38% from FY 2024). Net loss: NT$47.0m (flat on FY 2024). Announcement • Mar 03
iXensor Co., Ltd., Annual General Meeting, May 20, 2026 iXensor Co., Ltd., Annual General Meeting, May 20, 2026, at 10:00 Taipei Standard Time. Location: 1 floor no,399, jui kuang rd., neihu district, taipei city Taiwan New Risk • Mar 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$29m free cash flow). Share price has been highly volatile over the past 3 months (33% average weekly change). Negative equity (-NT$16m). Revenue is less than US$1m (NT$25m revenue, or US$784k). Market cap is less than US$10m (NT$239.2m market cap, or US$7.62m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). New Risk • Jan 28
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 22% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$29m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Negative equity (-NT$16m). Revenue is less than US$1m (NT$25m revenue, or US$784k). Minor Risk Market cap is less than US$100m (NT$352.2m market cap, or US$11.2m). New Risk • Aug 17
New major risk - Negative shareholders equity The company has negative equity. Total equity: -NT$16m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$29m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-NT$16m). Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Revenue is less than US$1m (NT$25m revenue, or US$818k). Market cap is less than US$10m (NT$233.3m market cap, or US$7.77m). Announcement • Mar 07
iXensor Co., Ltd., Annual General Meeting, May 20, 2025 iXensor Co., Ltd., Annual General Meeting, May 20, 2025, at 10:00 Taipei Standard Time. Location: 1 floor no,399, jui kuang rd., neihu district, taipei city Taiwan New Risk • Feb 28
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$50m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-NT$10m). Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Revenue is less than US$1m (NT$17m revenue, or US$514k). Market cap is less than US$10m (NT$197.8m market cap, or US$6.01m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). New Risk • Jan 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 40% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$50m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-NT$10m). Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Revenue is less than US$1m (NT$17m revenue, or US$513k). Market cap is less than US$10m (NT$210.1m market cap, or US$6.37m). New Risk • Jan 02
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 40% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$50m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-NT$10m). Revenue is less than US$1m (NT$17m revenue, or US$514k). Market cap is less than US$10m (NT$172.1m market cap, or US$5.23m). Minor Risk Shareholders have been diluted in the past year (40% increase in shares outstanding). New Risk • Aug 18
New major risk - Negative shareholders equity The company has negative equity. Total equity: -NT$10m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$50m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-NT$10m). Revenue is less than US$1m (NT$17m revenue, or US$525k). Market cap is less than US$10m (NT$230.4m market cap, or US$7.15m). New Risk • May 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$48m free cash flow). Revenue is less than US$1m (NT$21m revenue, or US$644k). Market cap is less than US$10m (NT$319.8m market cap, or US$9.86m). Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change). New Risk • May 08
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: NT$307.2m (US$9.48m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$48m free cash flow). Revenue is less than US$1m (NT$21m revenue, or US$645k). Market cap is less than US$10m (NT$307.2m market cap, or US$9.48m). Reported Earnings • May 05
Full year 2023 earnings released: NT$1.15 loss per share (vs NT$0.09 loss in FY 2022) Full year 2023 results: NT$1.15 loss per share (further deteriorated from NT$0.09 loss in FY 2022). Revenue: NT$20.9m (down 80% from FY 2022). Net loss: NT$63.2m (loss widened NT$58.3m from FY 2022). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings. Announcement • Mar 19
iXensor Co., Ltd., Annual General Meeting, Jun 03, 2024 iXensor Co., Ltd., Annual General Meeting, Jun 03, 2024. New Risk • Mar 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$41m free cash flow). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (NT$37m revenue, or US$1.2m). Market cap is less than US$100m (NT$450.4m market cap, or US$14.2m). New Risk • Nov 20
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$41m free cash flow). Share price has been highly volatile over the past 3 months (7.2% average weekly change). Minor Risks Revenue is less than US$5m (NT$37m revenue, or US$1.2m). Market cap is less than US$100m (NT$510.7m market cap, or US$16.2m). New Risk • Aug 14
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$41m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$41m free cash flow). Minor Risks Revenue is less than US$5m (NT$37m revenue, or US$1.2m). Market cap is less than US$100m (NT$551.3m market cap, or US$17.2m). Reported Earnings • Aug 17
First half 2022 earnings released: EPS: NT$0.23 (vs NT$0.95 loss in 1H 2021) First half 2022 results: EPS: NT$0.23 (up from NT$0.95 loss in 1H 2021). Revenue: NT$79.3m (up NT$72.1m from 1H 2021). Net income: NT$12.5m (up NT$62.1m from 1H 2021). Profit margin: 16% (up from net loss in 1H 2021). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Reported Earnings • May 02
Full year 2021 earnings released: NT$1.40 loss per share (vs NT$1.56 loss in FY 2020) Full year 2021 results: NT$1.40 loss per share (up from NT$1.56 loss in FY 2020). Revenue: NT$24.8m (up 56% from FY 2020). Net loss: NT$73.1m (loss narrowed 4.6% from FY 2020). Announcement • Apr 16
iXensor Co., Ltd., Annual General Meeting, Jun 30, 2022 iXensor Co., Ltd., Annual General Meeting, Jun 30, 2022. Announcement • Dec 23
iXensor Confirms PixoTest® COVID-19 Antigen Test Detects Omicron and Other Key Variants of Concern iXensor Co., Ltd. declared that its computer vision-powered PixoTest® COVID-19 Antigen Test effectively detects all major SARS-CoV-2 variants including Omicron (B.1.1.529) after completing two validation studies. In response to emerging new waves of the COVID-19 pandemic caused by Omicron across the globe, iXensor has conducted in-silico analysis followed by a laboratory validation using the recombinant protein of the Omicron variant. The in-silico study evaluated the amino acid sequences of N protein wild type and the Omicron variant (P13L, E31del, R32del, S33del, R203K, G204R), concluding that Omicron is detectable by PixoTest® COVID-19 Antigen Test. Furthermore, in the recombinant protein study, PixoTest® achieves the same limit of detection (0.25ng/ml) on those variants of concern as on the original wild type of SARS-CoV-2 used as a control. Both study results affirm that the PixoTest® COVID-19 Antigen Test can detect the latest Omicron variant effectively in addition to the previous confirmation on SARS-CoV-2 Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2). Most importantly, the sensitivity of PixoTest® COVID-19 Antigen Test is not affected by the Omicron and other Variants of Concern. Is New 90 Day High Low • Feb 27
New 90-day low: NT$19.05 The company is down 3.0% from its price of NT$19.70 on 27 November 2020. The Taiwanese market is up 15% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is down 4.0% over the same period. Is New 90 Day High Low • Nov 04
New 90-day low: NT$19.45 The company is down 10.0% from its price of NT$21.50 on 06 August 2020. The Taiwanese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is down 12% over the same period. 
